Russia to focus on more active import substitution in domestic pharma sector

Russia will focus on more active import substitution in the domestic pharmaceutical sector, that will be part of a new healthcare development strategy, designed until 2030, which was recently approved by the national government, according to media reports.

The new strategy outlines the key parameters for the industry's development through 2030. The previous version of the strategy was valid until the end of 2025.

The strategy involves the increase of the share of Russian-produced drugs to 90%. At the same time the share of domestically produced drugs in the list of vital and essential drugs should also increase to 90%.